Women’s Health Diagnostics Market: By Type, By Application and Geography

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

Women’s Health Diagnostics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Diagnostic Device, Diagnostic Tests), By Application (Breast Cancer, Infectious Disease, Osteoporosis, STD, Other) and Region

checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

Women’s Health Diagnostics Market size was valued at US$ 26,712.3 million in 2023 and is projected to reach US$ 44,434.5 million by 2030, at 7.35% CAGR from 2024-2030. the increased prevalence of infectious disorders among women, such as hepatitis and urinary tract infections, is expected to fuel growth over the projection period. Advances in medical science provide lucrative chances to combat women-specific problems such as infectious illnesses, osteoporosis, and breast cancer.

Key Developments:

  • In Oct 2024: Roche has gotten CE Mark clearance for VENTANA® HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx* to identify patients with metastatic breast cancer whose HER2 is low expressing for consideration as a targeted treatment with ENHERTU® (trastuzumab deruxtecan). The test, branded PATHWAY in the US, received US Food and Drug Administration (FDA) clearance in October 2022.
  • In Aug 2024: GE HealthCare collaborated with the University of California San Diego School of Medicine to explore some innovative MRI protocols and techniques that could prove useful in diagnosing diseases and disorders unique to female-specific pelvic disease and conditions. It also developed comprehensive educational products for clinicians. Such a research program bridges a significant gap in medical studies and treatments and seems to promise much in providing better healthcare for women's pelvic health. The results of this study should enable clinicians to make more informed decisions and diagnose conditions with speed and relative ease while giving easier access to quality care for the pelvic needs of women.
  • In May 2024: Lumos Diagnostics said it has completed the first phase of a Development Agreement to develop a novel fetal fibronectin (fFN) test for leading women's health company, Hologic, Inc. The focus of the Development Agreement is a next generation version of Hologic’s on- market fFN diagnostic product for pre-term birth.
  • In May 2024: BD (Becton, Dickinson and Company) formed a strategic alliance with Healthians, India's leading diagnostics service provider, in an effort to promote cervical cancer screening through innovative self-collection as an option for women in India to collect a sample in the comfort of their own homes.
  • In Jan 2024: BD (Becton, Dickinson & Company) the world's largest distributor of syringes, needles and surgical instruments, has partnered with the Kenyan Government through the National Cancer Institute-Kenya, to advance access to critical cancer diagnostics for women in Kenya. This is further advancing its commitment toward making progress in advancing health equity to underserved communities around the world.
  • In Jan 2024: Lumos said it entered into two new agreements with US-based women's health company, Hologic. One is an Intellectual Property agreement worth US$10.0 million, and the other is a Development Agreement worth US$4.7 million. The Agreements are regarding the development of a next-generation version of Hologic's on-market fFN diagnostic product for pre-term birth-a women's health product for which Hologic is the only manufacturer globally. Make the test compatible for use on the Lumos proprietary reader platform and enhance how it connects with other users' devices.
  • In Sep 2023: Hologic Inc and Bayer announced a collaboration that they will be using to deliver contrast-enhanced mammography solutions in order to enhance the detection of breast cancer for women in several countries located in Europe, Canada and the Asia Pacific region.
  • In March 2023, The US FDA has authorized Visby Medical's sexual health test. It is a second-generation PCR test that employs self-collected vaginal swabs to diagnose STIs such as trichomoniasis, chlamydia, and gonorrhoea.
  • In February 2023, Genetic Technologies Limited, a global leader in genomic-based diagnostics for health, wellness, and serious disease, has launched the 'World First' complete risk assessment test. This novel test assesses a woman's chance of acquiring breast and/or ovarian cancer due to either an inherited genetic mutation or the more frequent familial or sporadic malignancy.

summary download arrow Download Free Sample

Women’s Health Diagnostics Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

7.35%

Largest Market

North America

Fastest Growing Market

Asia Pacific

Women’s Health Diagnostics Market Dynamics

The market is expected to grow rapidly due to the rising prevalence of chronic and lifestyle-related disorders, the growing number of imaging and diagnostic centres, the increased adoption of point-of-care and rapid diagnostic tests, as well as player collaborations and partnerships. The growing prevalence of diseases such as breast cancer, ovarian and cervical cancer, autoimmune diseases, and infertility among women need thorough diagnosis. Furthermore, rising stress levels among women are increasing the burden of numerous illnesses such as obesity, the danger of drug abuse, and increased alcohol consumption, all of which contribute to infertility. For example, data updated by the Census Bureau in April 2022 showed that fertility rates among women aged 20 to 24 fell by 43% in recent years, with only 66.59 births per 1,000 women in that age range, indicating a 42.79% fall in fertility over the previous decades. Furthermore, according to research released and amended by the National Institutes of Health in January 2023, nearly 11% of women of reproductive age in the United States, ranging from 18 to 35 years old, have encountered fertility issues in recent years. As the occurrence of infertility among women rises, so does the demand for fertility testing and diagnosis in emerging nations, which is expected to drive market expansion throughout the forecast period.

Women’s Health Diagnostics Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 26,712.3 million

Market Size in 2030

US$ 44,434.5 million

Market CAGR

7.35%

By Type

  • Diagnostic Device
  • Diagnostic Tests

By Application

  • Breast Cancer
  • Infectious Disease
  • Osteoporosis
  • STD
  • Other

By Region

  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA

Key Features of the Report

  • The women’s health diagnostics market report provides granular level information about the Market size, regional Market share, historic Market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key Market developments, and key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the Market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the Market.
  • The report provides a plethora of information about Market entry strategies, regulatory framework, and reimbursement scenarios.
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis in addition to recent technology advancements and innovations in the market

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

The global women’s health diagnostics market size was valued at US$ 26,712.3 million in 2023 and is projected to grow at a CAGR of 7.35% by 2030.

The market is expected to grow rapidly due to the rising prevalence of chronic and lifestyle-related disorders, the growing number of imaging and diagnostic centers, the increased adoption of point-of-care and rapid diagnostic tests, as well as player collaborations and partnerships.

Due to the rising incidence of breast cancer, demand for breast cancer tests is increasing in both emerging and developed countries, which is likely to drive segment growth over the forecast period.

Market research is segmented based on type, application, and region.

North America is estimated to dominate with the highest CAGR over the forecast period.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Women’s Health Diagnostics Market Introduction 
2.1.Global Women’s Health Diagnostics Market  - Taxonomy
2.2.Global Women’s Health Diagnostics Market  - Definitions
2.2.1.Type 
2.2.2.Application
2.2.3.Region
3.Global Women’s Health Diagnostics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Women’s Health Diagnostics Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Women’s Health Diagnostics Market  By Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Diagnostic Device
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Diagnostic Tests
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
6.Global Women’s Health Diagnostics Market  By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Breast Cancer
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Infectious Disease
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Osteoporosis
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. STD
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Other
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7.Global Women’s Health Diagnostics Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Europe
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Asia Pacific (APAC)
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Middle East and Africa (MEA)
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. Latin America
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
8.North America Women’s Health Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Type  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.1.1.Diagnostic Device
8.1.2.Diagnostic Tests
8.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.2.1.Breast Cancer
8.2.2.Infectious Disease
8.2.3.Osteoporosis
8.2.4.STD
8.2.5.Other
8.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.3.1.United States of America (USA)
8.3.2.Canada
9.Europe Women’s Health Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Diagnostic Device
9.1.2.Diagnostic Tests
9.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Breast Cancer
9.2.2.Infectious Disease
9.2.3.Osteoporosis
9.2.4.STD
9.2.5.Other
9.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Germany
9.3.2.France
9.3.3.Italy
9.3.4.United Kingdom (UK)
9.3.5.Spain
10.Asia Pacific (APAC) Women’s Health Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Diagnostic Device
10.1.2.Diagnostic Tests
10.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Breast Cancer
10.2.2.Infectious Disease
10.2.3.Osteoporosis
10.2.4.STD
10.2.5.Other
10.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.China
10.3.2.India
10.3.3.Australia and New Zealand (ANZ)
10.3.4.Japan
10.3.5.Rest of APAC
11.Middle East and Africa (MEA) Women’s Health Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Diagnostic Device
11.1.2.Diagnostic Tests
11.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Breast Cancer
11.2.2.Infectious Disease
11.2.3.Osteoporosis
11.2.4.STD
11.2.5.Other
11.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.GCC Countries
11.3.2.South Africa
11.3.3.Rest of MEA
12.Latin America Women’s Health Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Diagnostic Device
12.1.2.Diagnostic Tests
12.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Breast Cancer
12.2.2.Infectious Disease
12.2.3.Osteoporosis
12.2.4.STD
12.2.5.Other
12.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Brazil
12.3.2.Mexico
12.3.3.Rest of LA
13. Competition Landscape
13.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
13.2.1.Abbott Laboratories
13.2.2.GE Healthcare
13.2.3.Mankind Pharma
13.2.4.Quest Diagnostic Inc
13.2.5.Siemens
13.2.6.BD Company
13.2.7.Hologic Inc
13.2.8.Procter & Gamble Co
13.2.9.Biome Rieux SA
13.2.10.Koninklijke Philips NV
13.2.11.Carestream Health
14. Research Methodology 
15. Appendix and Abbreviations 

Key Market Players

  • Abbott Laboratories
  • GE Healthcare
  • Mankind Pharma
  • Quest Diagnostic Inc
  • Siemens
  • BD Company
  • Hologic Inc
  • Procter & Gamble Co
  • Biome Rieux SA
  • Koninklijke Philips NV
  • Carestream Health

Related Industry Reports

Chronic Refractory Gout Pharmaceuticals Market

Familial Mediterranean Fever Pharmaceuticals Market

Australia Point of Care Diagnostics Market

Aseptic Sampling Market